Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases

New hepatitis B virus (HBV) infections are decreasing owing to improved antiviral therapy and increased HBV vaccination worldwide; however, the number of HBV infections remains a major cause of liver carcinogenesis. HBV triggers cytotoxic immunity to eliminate HBV-infected cells. Therefore, the HBV...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawanaka, Miwa, Nishino, Ken, Kawamoto, Hirofumi, Haruma, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613739/
https://www.ncbi.nlm.nih.gov/pubmed/34887645
http://dx.doi.org/10.3748/wjg.v27.i43.7497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613739/
https://www.ncbi.nlm.nih.gov/pubmed/34887645
http://dx.doi.org/10.3748/wjg.v27.i43.7497

Ejemplares similares